{"id":"W4399737375","doi":"10.1200/jco.2024.42.16_suppl.tps3180","title":"A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799544 (ARRY-134) as a single agent and in combination with PF-07799933 BRAF dimer inhibitor, in participants 16 years and older with advanced solid tumors.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre hospitalier universitaire de Québec; Ottawa Hospital; McGill University; Health Sciences Centre; McGill University Health Centre; Sunnybrook Health Science Centre","funders":"Pfizer","keywords":"Medicine; Tolerability; Pharmacokinetics; Maximum tolerated dose; Pharmacology; Open label; Oncology; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001744638,0.001615092,0.002068515,0.0004584999,0.0006435688,0.0008214778,0.001096757,0.001518671,0.004394723],"category_scores_gemma":[0.001027427,0.0007422097,0.001078531,0.0004596217,0.001221725,0.001473188,0.0004011287,0.004645081,0.001323482],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001115008,"about_ca_system_score_gemma":0.00206563,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008203369,"about_ca_topic_score_gemma":0.002021422,"domain_scores_codex":[0.9994751,0.0001725907,0.00001876139,0.0001354117,0.00007469126,0.0001235078],"domain_scores_gemma":[0.9990345,0.0001198587,0.0002067066,0.000106035,0.00008839498,0.0004445455],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4868301,0.3050648,0.006466994,0.0006382928,0.0007978546,0.0003927877,0.000514,0.002758713,0.1220718,0.0002956756,0.004201577,0.06996736],"study_design_scores_gemma":[0.1457394,0.8377059,0.007861506,0.00001419973,0.0002283446,0.0002423471,0.00006895157,0.0006262992,0.004977616,0.0002010445,0.002304386,0.00003000413],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9918646,0.0006343287,0.001015145,0.0002391534,0.00009991232,0.003878149,0.001105672,0.00009629234,0.001066763],"genre_scores_gemma":[0.9801877,0.0008917984,0.004128099,0.000905229,0.0001880642,0.006824916,0.002396567,0.00006336955,0.004414341],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004394723,"threshold_uncertainty_score":0.01470178,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09363379947207903,"score_gpt":0.4593080387546158,"score_spread":0.3656742392825368,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}